When a peptide COA reports 99% purity, the number most often refers to an area-normalized HPLC result. The laboratory has separated the sample, assigned a main peak, and calculated that peak as about 99% of the integrated detector response included in the result. It should not be read as 99% of the powder’s weight being peptide, or as proof that a vial contains 99% of the quantity printed on its label.
Identity, quantitative peptide content, milligrams per vial, bacterial endotoxin, and sterility are separate analytical questions. Some may involve chromatography, but they require different method designs, reference standards, calculations, or microbiological tests. A careful reading of 99% therefore begins with the narrower result the laboratory actually reported: the relative area of the assigned main peak under the stated chromatographic method.
Inside the HPLC Percentage
High-performance liquid chromatography separates components as a prepared sample moves through a column. Different components interact with the stationary phase and mobile phase in different ways, so they leave the column at different times. A detector records its response over time and produces the chromatogram, where the separated responses appear as peaks.
For an area-normalized purity calculation, the laboratory integrates the assigned main peak and the other peaks included under its method. The main-peak area is divided by the combined included peak area and expressed as a percentage. If the assigned peak contributes 99 units of integrated response out of an included total of 100, the reported area purity is 99%.
The word included carries much of the meaning. The column, mobile phase, gradient, detector type, detection wavelength, reporting threshold, baseline selection, and integration settings all influence which responses are separated, detected, and counted. An impurity that co-elutes with the main component may be incorporated into the main peak, while a component below the reporting threshold may be absent from the total used in the calculation.
Peak area is detector response rather than a universal measurement of mass. With UV detection, for example, different compounds can produce different responses at the selected wavelength, even at equal concentrations. Water, counterions, inorganic salts, some residual solvents, and formulation excipients may add to the material’s weight without appearing as equivalent peptide peaks in the area percentage.
HPLC area purity remains useful when read as a method-specific description of the chromatographic profile. It shows the relative prominence of the assigned main peak within the response included in that calculation, while other attributes remain for their own analytical procedures.
Chromatographic Purity and Peptide Content
HPLC can also be used for quantitative assay, but an assay is designed and calculated differently from main-peak area normalization. A suitable quantitative procedure compares sample response with an appropriately characterized reference standard or calibration model, operates over a defined reportable range, and applies the calculation basis and corrections required for the stated result. The report may express content as concentration, peptide per unit mass, or milligrams per vial, depending on the method and assignment.
This distinction is the reason 99% HPLC area purity and 10 mg peptide per vial cannot serve as interchangeable evidence. The first compares one integrated chromatographic response with the other responses included in the same calculation. The second is a quantitative content claim that requires a validated assay, an appropriate standard, and a clearly stated basis, including any relevant treatment of water, counterions, salt form, residual solvents, or other material.
A 2023 paper led by scientists from the United States Pharmacopeial Convention, with collaborators from the UK Medicines and Healthcare products Regulatory Agency, provides a useful measurement example. Its theoretical peptide reference material had 99.08% HPLC peak-area purity, yet the separately assigned content was 0.93 mg of peptide per mg of material on an anhydrous, free-base basis after counterions and other measured components were included in a mass-balance calculation. In that terminology, the counterion is not counted as peptide and the anhydrous result excludes water; applying the measured water content produced a lower as-is value for the material in its tested state.
The example concerns the value assignment of a theoretical peptide reference material, not a PSC product or a retail vial, and it offers no universal conversion from area purity to peptide content. Its value is in showing how a high chromatographic percentage can coexist with a lower mass-based peptide assignment because the two results describe different measurements.
Identity also requires its own evidence. LC-MS can support the expected molecular mass, and MS/MS or other structural techniques may add sequence or structural information. Depending on the peptide and the question being asked, stronger characterization may involve peptide mapping, amino acid analysis, NMR, chiral analysis, or other orthogonal methods; a matching mass alone cannot establish every aspect of structure, content, or purity.
A Measurement Map for the COA
A COA becomes easier to interpret when each result is matched to the question its method was designed to answer. The table below keeps those assignments separate without asking one test to carry conclusions that belong to another.
| Reader’s question | Relevant evidence | What the evidence cannot establish by itself |
|---|---|---|
| What proportion of the included chromatographic response belongs to the assigned main peak? | HPLC or another suitable chromatographic purity method, with the calculation basis stated | Net peptide content, milligrams per vial, complete identity, endotoxin level, or sterility |
| Does the material support the expected molecular identity? | LC-MS and, where needed, MS/MS or additional structural characterization | Peptide amount, chromatographic purity, endotoxin level, or sterility |
| How much peptide is present? | A validated quantitative assay using an appropriate reference standard and calculation basis | Complete identity, chromatographic impurity profile, endotoxin level, or sterility |
| Is bacterial endotoxin within a stated criterion? | A suitable bacterial-endotoxin procedure such as LAL, with the result and criterion reported | Sterility, identity, chromatographic purity, or peptide content |
Sterility sits outside an HPLC purity result and outside an endotoxin result. It requires a separate microbiological test and an appropriate quality framework, while LAL addresses bacterial endotoxin rather than viable microbial contamination. PSC’s guide to HPLC, LC-MS, and LAL testing explains those method boundaries in more detail.
Reading 99% Without Overreading It
The most accurate interpretation stays close to the wording on the report. A result identified as 99% HPLC area purity supports the conclusion that the assigned main peak accounted for about 99% of the integrated detector area included under that method and calculation. Extending the number to molecular identity, net peptide weight, labelled quantity, endotoxin, or sterility requires evidence that appears elsewhere in the analytical record.
When a vial carries a stated peptide amount, the relevant supporting result is a quantitative assay or content assignment reported in suitable units, such as milligrams per vial, along with the standard and calculation basis. When identity is the question, the reader should look for identity-supporting data. Endotoxin and sterility each need their own reported procedures and cannot be inferred from a clean-looking chromatogram.
At PSC, we read and present analytical percentages according to the method named on the report rather than allowing purity to become a catch-all description of product quality. A high area percentage can be a meaningful chromatographic result, but its value comes from knowing exactly what was integrated, how the percentage was calculated, and which questions remain for other tests.
Purity percentage alone is therefore insufficient because it answers only the question defined by the purity method. Once the result is kept within that boundary, 99% becomes useful evidence instead of a number carrying claims the analysis never measured.
Sources and context
- McCarthy et al., “Reference Standards to Support Quality of Synthetic Peptide Therapeutics,” Pharmaceutical Research (2023). This USP-led paper provides the theoretical 99.08% HPLC peak-area and 0.93 mg/mg anhydrous peptide-content example, along with the separate mass-balance and vial-content assignments.
- FDA/ICH Q6A, “Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products”. Used for the distinction among specifications, identity, assay, impurities, and microbiological testing.
- FDA, “Biotechnology Inspection Guide”. This non-binding 1991 inspection reference is used only for the distinct analytical roles of HPLC, mass spectrometry, peptide mapping, LAL, and sterility testing.
- EMA, “Draft guideline on setting specifications for related impurities in antibiotics”. This historical consultation draft is used for its technical discussion of area normalization, detector response, response factors, and mass-balance limitations, rather than as peptide-specific guidance.
- EMA/ICH Q2(R2), “Validation of Analytical Procedures”. The current guideline treats assay or potency, purity or impurities, and identity as distinct analytical purposes and centres validation on fitness for the intended purpose.
- CPTAC community recommendations, “Recommendations for the generation, quantification, storage and handling of peptides used for mass spectrometry-based assays”. Used for the separation of net peptide amount, chemical purity, identity characterization, and fit-for-purpose quantitative standards.
Research-use notice: Precision Synthetics Canada products and documentation are provided strictly for lawful, non-clinical laboratory research purposes only. COAs and testing records are not medical documents, safety guarantees, sterility guarantees, therapeutic endorsements, dosing guidance, or approval for human or veterinary use.